RECOVER
29.5.2024 14:01:30 CEST | Business Wire | Press release
Leading materials science company, Recover, joins the United Nations Fashion and Lifestyle Network as a Thought Partner for 2024, reaffirming its commitment to the Sustainable Development Goals (SDGs) and its dedication to forging ties across the global fashion and lifestyle industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529479473/en/
Recover™ is a global producer of recycled cotton fiber (Photo: Recover™)
As a producer of premium recycled cotton fiber, and the first in its space to scale its high-value technology globally, Recover is an important actor within the supply chain to inspire change. It recently restated its support of the Ten Principles of the United Nations Global Compact, and its commitment to taking actions that benefit the wider community was a key driver in the company’s selection as a Thought Partner for 2024.
The UN Fashion and Lifestyle Network, led by the United Nations Office for Partnerships and the Fashion Impact Fund, stands as a catalyst for sustainable development within the fashion and lifestyle sectors. It plays a key role in advancing the SDGs by connecting industry stakeholders, media, governments, and UN entities. Together Recover and the UN Fashion and Lifestyle Network share a vision of building resilient and traceable supply chains that are needed to achieve circularity.
Anders Sjöblom, CEO at Recover, commented: “Partnering with the UN Fashion and Lifestyle Network is a milestone for Recover as I believe that strategic partnerships are completely necessary to drive meaningful change within the fashion industry. At Recover, we believe that true innovation lies in creating value not just for our business and the industry but for society and the environment as well, and we look forward to contributing to a more sustainable future for fashion.”
Kerry Bannigan, Co-Founder, Conscious Fashion and Lifestyle Network added: “We are delighted to welcome Recover as a Thought Partner to the UN Fashion and Lifestyle Network for 2024. Their leadership and innovative approach to circular fashion will significantly contribute to our mission.”
Recover’s first appearance as a 2024 Thought Partner will take place at the UN Fashion and Lifestyle Network Annual Meeting on June 3rd at the United Nations headquarters in New York. In conversation with Vogue Business correspondent, Madeleine Schulz, Sjöblom will discuss his vision for the company and the challenges and opportunities in the industry today.
For press inquiries about the UN Fashion and Lifestyle Network Annual Meeting, please contact hannah.wesselby@recoverfiber.com.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to close the loop on fashion. As a fourth-generation, family-owned company with a 75-year history in the textile industry, Recover is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change makers to meet the industry’s sustainability targets.
About United Nations Fashion and Lifestyle Network
The United Nations Fashion and Lifestyle Network is a collaboration between the United Nations Office for Partnerships and the Fashion Impact Fund, dedicated to advancing sustainable development goals within the fashion and lifestyle sectors. For more information, visit https://sdgs.un.org/partnerships/action-networks/conscious-fashion-and-lifestyle-network.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529479473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom